Diethylpropion Stats & Data

• Use the lowest effective dose; for medical products do not exceed 75 mg/day total (25 mg IR TID or 75 mg SR QAM). Re‑dosing within the same day increases tachycardia, BP elevation, anxiety, and insomnia risk. • Short‑term use (historically ≤12 weeks) has been standard; longer courses raise tolerance and adverse‑event likelihood. • Rare but serious risks include pulmonary hypertension and acute arrhythmias; seek urgent care for persistent chest pain, exertional dyspnea, syncope, or ankle swelling. • Diethylpropion’s primary psychoactive effects are largely mediated by an aminoketone metabolite acting as a norepinephrine>dopamine releasing agent/inhibitor; this underlies strong appetite suppression with comparatively mild euphoria but meaningful cardiovascular load. • Avoid combining with MAOIs (including linezolid/methylene blue) due to risk of hypertensive crisis; a 14‑day washout is prudent. • Combining with other stimulants (including high‑dose caffeine or decongestants) substantially increases hyperthermia, hypertension, and seizure risk; avoid. • Combining with bupropion or tramadol increases seizure risk; both independently lower seizure threshold. • If choosing to use non‑medically, prefer oral over insufflation: nasal routes produce faster rises in plasma levels, greater BP/HR spikes, and more compulsive redosing; tablets contain binders that irritate/damage mucosa. • Do not crush or tamper with sustained‑release tablets (dose‑dumping). • Plan nutrition and fluids: stimulants suppress appetite and can cause dehydration; sip fluids regularly and include electrolytes during exertion/hot settings. • Space use: tolerance builds rapidly with daily/near‑daily use; allow several days to weeks between sessions to reduce compulsive use and adverse effects. • People with known cardiovascular disease, uncontrolled hypertension, or a history of stimulant‑induced anxiety/psychosis should avoid non‑medical use and seek medical advice before any exposure. • Monitor BP/HR during first exposures or dose changes; discontinue if marked or symptomatic elevations occur. • Insomnia is common; avoid afternoon/evening dosing and maintain sleep hygiene. • Hepatotoxicity appears unlikely compared with many agents, but most elimination is renal; older adults or those with renal impairment should be cautious with dosing and hydration.